Crescent Biopharma, Inc. Common Stock (CBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, CBIO trades at $18.91 with a market cap of $511.51M and a P/E ratio of -243.63. CBIO moved +3.63% today. Year to date, CBIO is +70.21%; over the trailing twelve months it is flat. Its 52-week range spans $8.72 to $27.41. Analyst consensus is strong buy with an average price target of $29.50. Rallies surfaces CBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for CBIO combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $18.91 |
| Market Cap | $511.51M |
| P/E Ratio | -243.63 |
| EPS | $-0.08 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.41 |
| 52-Week Low | $8.72 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $117.05M |
| Net Income | $-1.39M |
| Gross Margin | 95.09% |
7 analysts cover CBIO: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $29.50.